PMX-30063: Completed Phase II enrollment

PolyMedix completed enrollment of 215 patients in a double-blind, international Phase II trial evaluating 3 doses of once-daily IV PMX-30063 for 5 days vs. daptomycin for 7 days. Last month, PolyMedix...